Improved global safety monitoring of HIV drugs is needed

NewsGuard 100/100 Score
Jul 7 2011

With at least five million people worldwide taking antiretroviral therapy for HIV infection, the International Forum for Collaborative HIV Research, in a PLoS Medicine Policy Forum published on Tuesday, "recommends that improved and sustained global drug safety monitoring, including monitoring for substandard products, drug diversion, inappropriate use, and toxicity, is critical," a press release from PLoS states. In a recent meeting, key stakeholders "discussed the creation of a sustainable global pharmacovigilance system for antiretroviral drugs," according to the release (7/5).

http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Posted in: Disease/Infection News | Pharmaceutical News

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

New drug candidates show promise to reverse HIV immune evasion
Breakthrough vaccine strategy guides the immune system to generate HIV neutralizing antibodies
New research sheds light on how GLP-1 obesity drugs may change food cravings
Sugar abnormalities in the blood may promote biological aging and inflammation in HIV patients
Global HIV epidemic cannot be ended without keeping former prisoners, other patients engaged in care
Breakthrough study offers hope for an effective HIV cure
New report on HIV drug resistance: Challenges and recommendations
Researchers receive NIH grant to help develop gene therapy for HIV

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Researchers develop precise drugs to target HIV's Nef protein